StockData
MAIA Biotechnology, Inc. logo

MAIA Biotechnology, Inc. (MAIA) stock

MAIANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30
$1.30+0.05 (+4.00%)

Close on Nov 18, 2026Market cap $79.07MP/E –Yield –

MAIA Biotechnology r&d expenses

Research and development expenses are spending on new products and technology.

MAIA Biotechnology's R&D Expenses for the twelve months ending Sep 30, 2025 was $15.63M, up 45.3% year over year. For fiscal 2025 it was $453.75K, down 95.5% from the year before. The highest annual figure on record is $11.11M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$453.75K-95.5%
FY2024Dec 31, 2024$10.01M-9.9%
FY2023Dec 31, 2023$11.11M+24.4%
FY2022Dec 31, 2022$8.93M+155.5%
FY2021Dec 31, 2021$3.50M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.64M+76.4%
Q1 FY2026Mar 31, 2026$43.65K-98.5%
Q3 FY2025Sep 30, 2025$6.36M+138.4%
Q2 FY2025Jun 30, 2025$3.11M+51.6%
Q1 FY2025Mar 31, 2025$3.20M+37.8%
Q4 FY2024Dec 31, 2024$2.97M-20.1%
Q3 FY2024Sep 30, 2024$2.67M+2.6%
Q2 FY2024Jun 30, 2024$2.05M-21.0%
Q1 FY2024Mar 31, 2024$2.32M+5.7%
Q4 FY2023Dec 31, 2023$3.72M+55.3%
Q3 FY2023Sep 30, 2023$2.60M+10.9%
Q2 FY2023Jun 30, 2023$2.60M+22.6%
Q1 FY2023Mar 31, 2023$2.20M+5.7%
Q4 FY2022Dec 31, 2022$2.39M+58.7%
Q3 FY2022Sep 30, 2022$2.34M+116.6%
Q2 FY2022Jun 30, 2022$2.12M+229.1%
Q1 FY2022Mar 31, 2022$2.08M–
Q4 FY2021Dec 31, 2021$1.51M–
Q3 FY2021Sep 30, 2021$1.08M–
Q2 FY2021Jun 30, 2021$643.99K–

More MAIA Biotechnology figures

See a number that looks wrong?